Clinical trials: Chronic Obstructive Lung Disease (COLD), active
Chronic Obstructive Lung Disease (COLD), Heart Failure
Reforça't: A Community, Social, and Healthcare Program for Patients With Cardiorespiratory Conditions Upon Hospital Discharge
The goal of this randomized clinical trial is to determine whether an interdisciplinary, community-based intervention can reduce 30-day hospital readmissions and improve functional outcomes in patients aged 65 or older with…
- Trial name
- R't (NCT06897410)
- Testing
- Interdisciplinary Program for Post-Hospitalization / Hospital at home Management and Long-Term Outcomes in Older Adults with Chronic Cardiorespiratory Condition
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Corporació de Salut del Maresme i la Selva
Falls Injury, Falls
Potential of Interface Care Models to Deliver More Appropriate Care to Patients With Acute Medical Illness
Every country in the world is experiencing growth in both the size and the proportion of older persons. As a result of the changes, the profile and needs of people with medical illnesses have evolved.
- Conditions
- Falls Injury, Falls, Hospitalization in Acute Care, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT07536035
- Where
- Singapore
- Volunteers
- 220 people
- Sponsor
- National University Hospital, Singapore
Chronic Obstructive Lung Disease (COLD)
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension compared with the placebo in the treatment of Chinese patients with COPD.
- Trial name
- NCT07140328
- Testing
- HSK39004 Dry Powder Inhaler -0.75mg BID, HSK39004 Dry Powder Inhaler -1.5mg BID, HSK39004 Inhalation Suspension -3mg BID
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Chronic Obstructive Lung Disease (COLD)
Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD
This clinical trial evaluates the long-term safety and efficacy of 0.75 mg HSK39004 Dry Powder Inhaler administered twice daily for 52 weeks in subjects aged 40 to 80 years with moderate-to-severe stable chronic obstructive…
- Trial name
- NCT07425210
- Testing
- HSK39004 Dry Powder Inhaler -0.75mg BID
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.